9月14日，诺华盘中上涨3.19%，报139.49美元/股，成交额7223.19万美元。消息面上，诺华前20大股东Artisan Partners公开呼吁改组董事会，其董事总经理David Samra指出公司需加强对并购的监督，矛头直指120亿美元Avidity收购案及此前已计提减值的MorphoSys收购案，市场将此解读为推动公司治理改善的积极信号。与此同时，汇丰将诺华评级上调至"持有"，目标价110瑞士法郎；加拿大皇家银行以120瑞士法郎目标价启动覆盖。此前一周，诺华因pelacarsen心血管III期试验失败、DM1药物del-desiran III期未达主要终点等三项临床接连受挫，股价一度重挫逾13%，本次反弹系超跌后多重利好共振所致。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.